Seeking Alpha

Cubist takes exception to generic threat

  • Fresenius Kabi USA sends Cubist Pharmaceuticals (CBST +0.1%) a letter notifying it that it has submitted an ANDA for a generic version of Cubicin (daptomycin for injection) which, according to Cubist, is protected by six Orange Book-listed patents expiring between 2016 and 2028. Fresenius alleges that five of the patents are invalid and unenforceable. Cubist intends to file a complaint with the FDA within 45 days. Once it files its lawsuit, the FDA will institute an automatic 30-month stay on its approval decision.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: